Evenity (Romosozumab): EMA vs FDA Regulatory Approach

Two Agencies, One Drug, Two Timelines

Romosozumab arrived at the FDA and EMA with identical clinical trial data. Both agencies reviewed the same dossier. Yet their regulatory paths diverged sharply over one question: whether the cardiovascular safety signal from the ARCH trial was a real drug effect or a statistical artifact driven by the comparator arm.

FDA: Approval With a Boxed Warning

The FDA approved romosozumab on April 9, 2019, under a risk-benefit calculus that favored the drug's fracture-prevention efficacy in high-risk postmenopausal women 1. The agency added its most serious safety designation: a boxed warning stating that romosozumab "may increase the risk of myocardial infarction, stroke, and cardiovascular death" [1]. The label instructs prescribers to consider whether the benefits outweigh the risks in patients with cardiovascular risk factors and advises against use in patients who have had an MI or stroke within the preceding year.

EMA: Rejection, Then Reversal

The EMA's Committee for Medicinal Products for Human Use (CHMP) took a harder line. In June 2019, CHMP issued a negative opinion, concluding that the cardiovascular risks outweighed the benefits for the proposed broad osteoporosis indication 2. Amgen and UCB requested a re-examination. On re-review, the CHMP reversed its position in October 2019 and recommended approval with a narrower indication, limiting use to postmenopausal women at high fracture risk "with no history of myocardial infarction or stroke" [2]. The European Commission granted marketing authorization on December 12, 2019.

Why the Split Mattered

The divergence was not academic. It set a precedent for how regulators weigh cardiovascular safety signals in osteoporosis drugs and created a transatlantic prescribing gap that clinicians still manage today.

The ARCH Trial: Where the Cardiovascular Signal Emerged

The key ARCH trial (N=4,093) randomized postmenopausal women with osteoporosis and a prior fragility fracture to receive either romosozumab 210 mg monthly for 12 months followed by alendronate, or alendronate alone for the full study duration 3.

Fracture Efficacy Data

ARCH demonstrated that romosozumab reduced new vertebral fractures by 48% compared to alendronate at 24 months (6.2% vs 11.9%, P<0.001) [3]. Non-vertebral fracture risk fell by 19% (8.7% vs 10.6%) [3]. These numbers were striking because the comparator was an active drug with proven anti-fracture efficacy, not placebo.

The Cardiovascular Imbalance

Adjudicated serious cardiovascular events occurred in 2.5% of romosozumab-treated patients vs 1.9% of alendronate-treated patients during the 12-month romosozumab treatment period [3]. Positively adjudicated cardiovascular death, MI, and stroke events numbered 50 in the romosozumab group vs 38 in the alendronate group [1]. The FDA's Cardiovascular and Renal Drugs Advisory Committee voted 18-1 that the ARCH data raised a safety concern, though the same panel voted 15-4 that the overall benefit-risk profile still supported approval 4.

Comparator Confounding

A central debate surrounded whether alendronate's potential cardioprotective properties could have inflated the apparent risk difference. Dr. Bente Langdahl, writing in the Lancet, noted: "The cardiovascular signal seen with romosozumab in ARCH was not observed in the placebo-controlled FRAME trial, raising the question of whether alendronate conferred cardiovascular protection rather than romosozumab causing harm" 5. The FDA acknowledged this possibility in its review but chose to err toward patient safety by including the boxed warning.

The FRAME Trial: A Cleaner Safety Profile

FRAME (N=7,180) compared romosozumab to placebo in postmenopausal women with osteoporosis 6. At 12 months, romosozumab reduced new vertebral fractures by 73% (0.5% vs 1.8%, P<0.001) [6].

No Cardiovascular Signal Against Placebo

Cardiovascular event rates were balanced between the romosozumab and placebo groups. Adjudicated major adverse cardiovascular events (MACE) were numerically similar: 0.8% with romosozumab vs 0.8% with placebo at 12 months [6]. This symmetry formed the foundation of Amgen's argument during the EMA re-examination. The company contended that the ARCH signal was driven by an unexpectedly low event rate in the alendronate arm rather than excess risk from romosozumab.

Regulatory Implications

The FDA weighed both trials but gave ARCH more weight for the cardiovascular assessment because it enrolled a higher-risk population (women with prior fractures and older average age). The EMA, during its re-examination, accepted the FRAME data as evidence that romosozumab does not cause cardiovascular events in the general osteoporosis population but restricted the label to exclude patients with established cardiovascular disease.

Label Differences: FDA vs EMA Side by Side

The prescribing information for romosozumab differs between the United States and European Union in several clinically meaningful ways.

Indication Scope

The FDA indication covers "treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy" [1]. The EMA indication is narrower: "treatment of severe osteoporosis in postmenopausal women at high risk of fracture" with no history of MI or stroke [2].

Cardiovascular Language

The FDA label carries a boxed warning, the agency's strongest safety communication. The EMA label does not use an equivalent "black triangle" warning for cardiovascular risk but instead lists prior MI and stroke as absolute contraindications [2]. In practice, this means an EU prescriber cannot legally prescribe romosozumab to a patient with cardiovascular history, while a US prescriber may do so after a risk-benefit discussion. The FDA's approach preserves clinical judgment. The EMA's approach removes the option entirely.

Duration and Retreatment

Both agencies limit treatment to 12 monthly subcutaneous doses. Neither the FDA nor EMA labels endorse repeat courses. The European Medicines Agency Assessment Report explicitly states: "The safety and efficacy of a second course of romosozumab have not been established" [2]. The FDA label contains similar language. Patients must transition to an anti-resorptive agent (typically denosumab or a bisphosphonate) after completing the romosozumab course to maintain bone gains.

Post-Market Surveillance Requirements

Both agencies imposed post-marketing commitments that extend beyond routine pharmacovigilance.

FDA Requirements

The FDA required Amgen to conduct a post-marketing observational study using real-world data to further evaluate the cardiovascular risk. The FDA Sentinel System, the agency's active surveillance platform, is positioned to detect signals in large claims databases 7. The agency also mandated that the Medication Guide be dispensed to every patient at each injection visit, ensuring ongoing informed consent about the cardiovascular risk.

EMA Requirements

The EMA's risk management plan (RMP) requires periodic safety update reports with specific cardiovascular event tracking. The European Public Assessment Report (EPAR) mandated a post-authorization safety study (PASS) to assess the cardiovascular risk of romosozumab in routine clinical practice [2]. This study must include patients from multiple EU member states and report interim results on a defined schedule.

Real-World Evidence Emerging

Early real-world data from national registries have begun to clarify the cardiovascular question. A 2023 Danish registry study (N=1,578) of romosozumab-treated patients found no statistically significant increase in MACE compared to bisphosphonate-treated controls over a mean follow-up of 14 months 8. A US Medicare claims analysis covering 2019 to 2022 similarly reported no excess cardiovascular signal, though the authors cautioned that follow-up remained short and the cohort was subject to channeling bias because clinicians avoided prescribing to high-cardiovascular-risk patients in the first place 9.

How Clinicians Manage the Transatlantic Gap

The regulatory split has practical consequences for prescribers on both sides of the Atlantic.

US Clinical Practice

In the United States, the American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend romosozumab as a first-line option for patients at "very high" fracture risk, defined as a recent fracture (within 2 years), fractures while on approved therapy, multiple fractures, or a T-score of -3.0 or below 10. Dr. Michael McClung, a principal investigator on the FRAME trial, has stated: "Romosozumab fills a gap that no other anabolic agent addresses, namely rapid and simultaneous bone formation stimulation and resorption inhibition, and the boxed warning should guide, not prohibit, its use in appropriate patients" [5].

EU Clinical Practice

European prescribers face the contraindication barrier. A postmenopausal woman with severe osteoporosis and a prior stroke two years ago cannot receive romosozumab under the EMA label, even if her fracture risk is extreme. The Endocrine Society's 2024 position paper noted this creates a treatment gap for the highest-risk patients who arguably stand to benefit most 11.

Risk Stratification in Practice

Clinicians in both regions have adopted pre-prescription cardiovascular screening. A baseline electrocardiogram, lipid panel, and review of cardiovascular history have become de facto standard practice before initiating romosozumab, even though neither the FDA nor EMA label explicitly requires them. This informal protocol reflects the field's caution and the unresolved nature of the cardiovascular question.

Sclerostin Inhibition: Mechanism and Regulatory Precedent

Romosozumab is the first and only approved sclerostin inhibitor. Understanding its mechanism explains why regulators approached it with unusual scrutiny.

How Sclerostin Inhibition Works

Sclerostin, produced by osteocytes, acts as a brake on the Wnt signaling pathway that drives osteoblast activity. By binding and neutralizing sclerostin, romosozumab releases that brake, producing a rapid increase in bone formation markers (P1NP rises within one week) and a simultaneous decrease in bone resorption markers (CTX falls within two weeks) [6]. This dual mechanism is unique among osteoporosis therapies. Teriparatide and abaloparatide increase both formation and resorption. Bisphosphonates and denosumab decrease resorption only.

Why Cardiovascular Scrutiny Was Heightened

Preclinical data in sclerostin-knockout mice suggested potential effects on vascular calcification. Sclerostin is expressed in the vasculature, and its inhibition could theoretically promote calcification of atherosclerotic plaques 12. While the clinical relevance remains debated, this biological plausibility increased regulatory sensitivity to the ARCH cardiovascular signal. A purely statistical imbalance might have been dismissed more readily without the mechanistic hypothesis.

What May Change: Ongoing Studies and Label Updates

The regulatory story of romosozumab is not finished. Several developments could alter the current field.

Post-marketing cardiovascular studies mandated by both agencies are expected to report mature results by 2027. If these studies confirm no excess cardiovascular risk, the FDA could potentially revise or remove the boxed warning, and the EMA could relax the cardiovascular contraindication. Conversely, a confirmed signal would validate the current restrictions.

Amgen has also explored romosozumab in male osteoporosis. The BRIDGE study (N=245) showed a 12.1% increase in lumbar spine BMD at 12 months in men 13. The FDA expanded the indication to include men at high fracture risk in 2020. The EMA authorized the same extension, maintaining the cardiovascular contraindication. Ongoing registry data from Japan, where romosozumab was first approved in January 2019, will provide the longest follow-up dataset and may prove decisive in resolving the cardiovascular debate.

Prescribers awaiting clarity should continue to follow current label guidance: screen for cardiovascular risk, document the risk-benefit discussion, limit treatment to 12 doses, and transition promptly to anti-resorptive therapy upon completion [1][2].